Core Viewpoint - The company clarifies that recent online articles suggesting a partnership with a financial platform are inaccurate, emphasizing that no cooperation arrangements are currently intended [1] Group 1: Company Announcement - The company has noted articles online regarding a potential collaboration with a financial platform, which claims discussions on capital operation strategies took place [1] - The articles suggest that the financial platform would provide comprehensive support, focusing on strategic investments, acquisitions across the entire industry chain, and effective market value management strategies [1] - The company states that the only interaction with the financial platform was a site visit to its wholly-owned subsidiary, Shandong Victory Steel Pipe Co., Ltd., and no discussions on the mentioned topics occurred during this visit [1] Group 2: Clarification of Misrepresentation - The company emphasizes that the content of the articles does not align with the facts, and it has no intention of entering into any cooperation arrangements with the financial platform as of the announcement date [1] - The articles also claimed that both parties would explore more cooperation opportunities in the future, which the company refutes [1]

Core Viewpoint - Spring Medical (01858) has made a strategic investment of 50 million RMB in a healthcare industry fund, which is expected to enhance its core competitiveness and overall profitability [1] Group 1: Investment Details - Spring Medical has invested 50 million RMB in the Nanchang Defu Phase IV Equity Investment Fund, acquiring a 9.2105% share of the fund [1] - The fund primarily targets growth and mature enterprises/projects in the healthcare sector, aligning with the company's main business [1] Group 2: Strategic Implications - The investment is in line with the company's strategic development direction, facilitating its industrial layout [1] - By leveraging the investment experience and resource advantages of its partners, the company aims to integrate industrial operations and capital management, fostering a virtuous cycle of collaborative development [1] - This move is expected to contribute to the company's sustainable, safe, healthy, and stable high-quality growth [1]

Core Viewpoint - Spring Medical (01858) has announced an investment in the Nanchang Defu Phase IV Equity Investment Fund Partnership, focusing on the healthcare industry, which aligns with the company's main business [1] Investment Details - The company will invest 50 million RMB, representing 9.2105% of the fund's total shares [1] - The investment targets growth and mature enterprises/projects in the healthcare sector [1] Strategic Implications - This investment aligns with the company's strategic development direction and enhances its industrial layout [1] - Collaboration with partners is expected to leverage investment experience and resource advantages, promoting deep integration of industrial operations and capital management [1] - The initiative aims to create a virtuous cycle of collaborative development, enhancing the company's core competitiveness and overall profitability [1] - The goal is to achieve sustainable, safe, healthy, and stable high-quality development for the company [1]

Core Viewpoint - The company announced the establishment of a private equity fund in collaboration with Zhimi Capital and other investors, aiming to enhance its investment capabilities in the semiconductor and related sectors [1][2]. Group 1: Fund Details - The fund, named Shanghai Zhimi Panfeng Venture Capital Partnership (tentative), has a target fundraising scale of RMB 1.5 billion, with Zhimi Capital contributing RMB 15 million, representing 1% of the total [1]. - The company’s wholly-owned subsidiary, Zhongwei Lingang, plans to invest up to RMB 735 million, accounting for no more than 49% of the fund [1]. - The fund's duration is tentatively set for 7 years, with 4 years for investment and 3 years for exit, and it may be extended up to 2 times, each for no more than 1 year [2]. Group 2: Investment Focus - The fund will primarily focus on equity investments in leading companies with technological barriers, particularly in the semiconductor and broader semiconductor sectors, while also covering high-quality investment targets in strategic emerging industries [2]. - At least 80% of the actual total investment at the end of the fund's duration will be directed towards companies in the integrated circuit industry and its upstream and downstream sectors [2]. Group 3: Company Strategy and Performance - The investment aligns with the company's strategic development direction, enhancing its industrial layout and promoting a synergistic development cycle [3]. - Since its listing, the company has invested over RMB 2 billion in approximately 40 upstream and downstream enterprises, achieving a floating profit of over RMB 5 billion [4]. - The company reported a revenue of approximately RMB 9.065 billion for 2024, a year-on-year increase of about 44.73%, with a net profit of approximately RMB 1.388 billion, up 16.52% year-on-year [4].

Group 1: Company Operations and Strategy - The company is focusing on strengthening its iron ore main business, solidifying its non-ferrous industry, increasing investment increments, and optimizing supporting services [1][2][3] - The company aims to transform from a pure iron ore producer to a comprehensive mineral resource producer and service provider, enhancing value-added services [3] - The company is implementing a dual-driven model combining production operations and capital operations to enhance market competitiveness [3] Group 2: Investor Relations and Communication - The company has not yet officially listed the 100% equity and debt of its subsidiary, Jingan Mining, for sale, and investors are advised to pay attention to future announcements [1][2] - There is currently no collaboration with Baowu Resources, despite inquiries regarding potential partnerships [1][2] - The company has clarified that Yongfeng Steel Group is not a major customer and has not entered the top ten shareholders through stock purchases [1][2] Group 3: Market Conditions and Financial Performance - The company is aware of the potential decline in iron ore prices in 2025 and is focusing on cost optimization to enhance profitability [3] - The company is committed to strict cost control measures, including reducing procurement costs and enhancing asset efficiency [3] - The company has disclosed plans for the pre-listing transfer of Jingan Mining's 100% equity and debt, with further updates to be provided in future announcements [3]